Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.2 USD | +0.91% |
|
-4.90% | +22.14% |
06-04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
06-03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
Business Summary
Number of employees: 1,453
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Tumor Treating Fields
100.0
%
| 538 | 100.0 % | 509 | 100.0 % | -5.30% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
68.7
%
| 407 | 75.7 % | 350 | 68.7 % | -14.05% |
Germany
11.8
%
| 46 | 8.6 % | 60 | 11.8 % | +30.55% |
Others
8.7
%
| 0 | 0.0 % | 44 | 8.7 % | - |
Japan
6.2
%
| 33 | 6.1 % | 32 | 6.2 % | -3.40% |
Greater China
4.6
%
| 21 | 4.0 % | 23 | 4.6 % | +8.87% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Asaf Danziger
CEO | Chief Executive Officer | 56 | 01-12-31 |
Ashley Cordova
DFI | Director of Finance/CFO | 45 | 14-05-31 |
Moshe Giladi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Nicolas Leupin
CTO | Chief Tech/Sci/R&D Officer | 50 | 01-03 |
Chief Operating Officer | 66 | 12-01-04 | |
Ingrid Goldberg
IRC | Investor Relations Contact | - | 21-06-30 |
Barak Ben Arye
LAW | General Counsel | 48 | 17-12-31 |
Corporate Officer/Principal | - | - | |
Uri Weinberg
PRN | Corporate Officer/Principal | 46 | 08-02-29 |
Michael Puri
HRO | Human Resources Officer | 55 | 23-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Doyle
CHM | Chairman | 61 | 03-12-31 |
Kin Yip Leung
BRD | Director/Board Member | 63 | 11-08-04 |
David Hung
BRD | Director/Board Member | 67 | 18-05-30 |
Timothy Scannell
BRD | Director/Board Member | 60 | 21-02-04 |
Jeryl Hilleman
BRD | Director/Board Member | 67 | 18-07-24 |
Tony Vernon
BRD | Director/Board Member | 69 | 05-12-31 |
Asaf Danziger
CEO | Chief Executive Officer | 56 | 01-12-31 |
Martin Madden
BRD | Director/Board Member | 64 | 17-05-09 |
Kristin Stafford
BRD | Director/Board Member | 43 | 23-03-27 |
Allyson Ocean
BRD | Director/Board Member | 53 | 23-02-22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 107,611,077 | 97,640,581 ( 90.73 %) | 0 | 90.73 % |
Company contact information
NovoCure Ltd.
No. 4 The Forum Grenville Street
JE2 4UF, St. Helier
+44 15 3475 6700
http://www.novocure.com![address NovoCure Limited(NVCR)](https://cdn.zonebourse.com/static/address/24157014.png)
Sector
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.14% | 1.94B | |
+75.69% | 12.57B | |
+11.37% | 7.03B | |
-30.89% | 6.68B | |
+9.11% | 5.25B | |
-19.22% | 4.67B | |
+19.81% | 4.07B | |
-20.81% | 3.77B | |
-28.74% | 2.66B | |
-2.35% | 1.99B |
- Stock Market
- Equities
- NVCR Stock
- Company NovoCure Limited